Abstract
Artificial intelligence has yet to produce a drug from scratch. But the technology is well advanced in pharmaceutical industry laboratories, despite initial pushback at the research bench. Major drug companies are designing their own technology and partnering with AI platform developers, many of which are also drug discovery companies, for support in target identification, drug design, and clinical trial analysis. The goal is to connect research and development from end to end. Two leading AI technology companies claim they’re ready to provide the full connection, but some research managers question the effectiveness of AI at various points on the route from early discovery to the still-elusive AI-derived drug. In December, Roche announced a deal with Recursion, an artificial intelligence technology developer with its own drug discovery program. Roche will access Recursion’s AI-driven drug discovery platform to identify and develop up to 40 new medications for cancer and neurological conditions. Hailed
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
